Roche beats forecasts on new drugs and one-off gain

By Ludwig Burger BASEL, Switzerland (Reuters) – Switzerland's Roche beat market expectations for adjusted net income in the first six months of the year, helped by cancer drug sales but also inflated by a one-off gain from its pensions scheme. Core earnings per share, adjusted for certain items, rose 7 percent to 7.74 Swiss francs ($7.86), where analysts had expected 7.52 francs on average. Deutsche Bank analyst Tim Race said that excluding that effect, results were broadly in line with expectations.

More here:
Roche beats forecasts on new drugs and one-off gain